

7 January 2020

***Meiji Seika Pharma and Kadmon Enter into Strategic Partnership  
to Develop and Commercialize KD025 for GVHD treatment  
in Japan and Asian Countries***

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, “Meiji”) today announced that it has entered into a strategic collaboration and partnership with Kadmon Corporation, LLC (Headquarters: New York, U.S., President and CEO: Harlan W. Waksal) to form a joint venture to exclusively develop and commercialize KD025 in Japan and certain other Asian countries.

Under the terms of the transaction agreements, the joint venture receives rights to develop and commercialize KD025 in Japan and 12 other Asian countries. Kadmon will receive payments such as potential development, regulatory and commercial milestone payments, and royalty payments on sales of KD025. The joint venture is domiciled in Japan with shared oversight between Kadmon and Meiji.

KD025, Kadmon’s ROCK2 inhibitor, is being studied in a pivotal clinical trial in the United States for the treatment of chronic graft-versus-host disease (cGVHD). In October 2018, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to KD025 for the treatment of cGVHD after two or more lines of systemic therapy.

**About Kadmon**

Kadmon Corporation, LLC is a wholly owned subsidiary of Kadmon Holdings, Inc. (NYSE: KDMN), a biopharmaceutical company developing innovative products for significant unmet medical needs. Kadmon’s product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology. (URL: <https://kadmon.com/>)